Hypermarcas (OTCMKTS:HYPMY) Short Interest Update

Hypermarcas (OTCMKTS:HYPMYGet Free Report) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totaling 3,024 shares, a growth of 18,800.0% from the March 15th total of 16 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average trading volume of 50,876 shares, the days-to-cover ratio is presently 0.1 days.

Hypermarcas Price Performance

OTCMKTS:HYPMY traded up $0.03 during mid-day trading on Friday, reaching $4.70. The stock had a trading volume of 5,943 shares, compared to its average volume of 21,100. The stock has a 50-day simple moving average of $4.37 and a two-hundred day simple moving average of $4.42. The stock has a market capitalization of $2.98 billion, a PE ratio of 13.82 and a beta of 0.75. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.27 and a quick ratio of 0.84. Hypermarcas has a 12 month low of $3.29 and a 12 month high of $5.50.

Hypermarcas (OTCMKTS:HYPMYGet Free Report) last announced its quarterly earnings data on Thursday, March 12th. The company reported $0.13 earnings per share (EPS) for the quarter. The business had revenue of $414.22 million for the quarter. Hypermarcas had a net margin of 15.71% and a return on equity of 10.27%.

About Hypermarcas

(Get Free Report)

Hypermarcas SA is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.

Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products.

Further Reading

Receive News & Ratings for Hypermarcas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypermarcas and related companies with MarketBeat.com's FREE daily email newsletter.